companiesCompany

ImmunityBio

ImmunityBio makes Anktiva, the IL-15 superagonist approved with BCG for bladder cancer in 2024.

Nogapendekin alfa inbakicept (Anktiva); NK-cell and vaccine programmes; long regulatory path including a 2023 CRL.

Headquarters

San Diego, CA, US

Type

biotech · IBRX

Website

immunitybio.com

Products

1top

ApprovedIL-15 superagonist (intravesical, with BCG)

Nogapendekin alfa inbakicept · Anktiva

Nogapendekin alfa inbakicept is an engineered version of the immune-boosting protein IL-15, given with BCG into the bladder, approved in 2024 for early bladder cancer that BCG alone no longer controls.

Connected

4top

Pages like this

not linked directly; found by shared links

Trial
QUILT 3.032
Shares Nogapendekin alfa inbakicept, Bladder & urothelial cancer.
Term
BCG-unresponsive
Shares Nogapendekin alfa inbakicept, Bladder & urothelial cancer.
Technology
Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)
Shares Nogapendekin alfa inbakicept, Bladder & urothelial cancer.
Technology
Cytokines & engineered cytokines
Shares Nogapendekin alfa inbakicept, Bladder & urothelial cancer.

ImmunityBio

Products

Connected

Pages like this

cancers

fronts

drugs

ideas